LP
LAB icon

LMR Partners’s Standard BioTools LAB Stock Holding History

LMR Partners’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-27,176
Closed -$30K – 1194
2022
Q3 		$30K Hold
27,176
– – ﹤0.01% 1137
2022
Q2 		$43K Buy
+27,176
New +$67.2K ﹤0.01% 1170
2018
Q3 		– Sell
-24,169
Closed -$144K – 434
2018
Q2 		$144K Buy
+24,169
New +$138K 0.01% 439

Other funds holding LAB

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JCP
Jennifer C. Price $75.5M AUM 6.25% 1-Year Est. Return

LMR Partners's LAB Position: Q4 2022 in Review

LMR Partners sold out of Standard BioTools (LAB) in Q4 2022, closing a stake of 27,176 shares — an estimated $30K sold.

LMR Partners first reported a position in LAB in Q2 2018 and held it in 3 quarters. The position peaked at $144K in Q2 2018. 68 funds tracked by Wall St. Rank hold LAB as of Q4 2022.

  • LMR Partners reported no remaining Standard BioTools position as of Q4 2022 after selling out during the quarter.
  • LMR Partners sold 27,176 Standard BioTools shares in Q4 2022, an estimated $30K.
  • LMR Partners first reported a position in Standard BioTools in Q2 2018 and held it in 3 quarters.
  • LMR Partners's Standard BioTools position peaked at $144K in Q2 2018.
  • 68 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2022.

Based on LMR Partners's 13F filing for Q4 2022, filed 14 Feb 2023.